DeepMed Research

Cimlanod

Generic Name: Cimlanod

Drug Type: Small Molecule

Chemical Formula: C_₅H_₇NO_₄S

CAS Number: 1620330-72-4

Unique Ingredient Identifier: 2US4FK1EPV

Background: Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers).

Clinical Trials

A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: BMS-986231 Formulation C
Drug: BMS-986231 Formulation D
Drug: BMS-986231 Formulation B
Drug: BMS-986231 Formulation A

First Posted Date: 2019-03-26

Last Posted Date: 2019-10-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60

Registration Number: NCT03891108

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic

Phase 2

Completed

Conditions: Myocardial Failure
Congestive Heart Failure
Heart Decompensation
Cardiac Failure

Interventions: Drug: BMS-986231
Drug: Furosemide
Drug: Placebo

First Posted Date: 2018-11-05

Last Posted Date: 2021-02-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 23

Registration Number: NCT03730961

Locations: 🇬🇧
Richmond Pharmacology, London, United Kingdom
🇬🇧
Glasgow Clinical Research Facility, Glasgow, United Kingdom

An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function

Phase 1

Completed

Conditions: Liver Dysfunction
Liver Insufficiency
Hepatic Failure
Myocardial Failure
Heart Decompensation
Cardiac Failure
Congestive Heart Failure

Interventions: Drug: BMS-986231

First Posted Date: 2018-05-04

Last Posted Date: 2020-08-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 76

Registration Number: NCT03515980

Locations: 🇵🇱
KO-MED Centra Kliniczne Lublin, Lublin, Poland
🇭🇺
Semmelweis Egyetem Altalanos Orvostudomanyi Kar, Budapest, Hungary
🇵🇱
BioVirtus Centrum Medyczne, Jozefow, Poland

and more 1 locations

A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

Phase 2

Completed

Conditions: Heart Failure
Cardiac Failure
Reduced Ventricular Ejection Fraction

Interventions: Drug: HNO Donor
Drug: Nitroglycerin (NTG)
Other: Placebo

First Posted Date: 2017-11-30

Last Posted Date: 2020-07-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 49

Registration Number: NCT03357731

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸
Inova Heart and Vascular Institute, Falls Church, Virginia, United States

and more 4 locations

A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function

Phase 1

Completed

Conditions: Cardiac Failure
Myocardial Failure
Congestive Heart Failure
Kidney Failure
Renal Failure

Interventions: Drug: BMS-986231

First Posted Date: 2017-11-06

Last Posted Date: 2019-09-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT03332186

Locations: 🇨🇿
Local Institution, Praha 7, Czechia
🇵🇱
Samodzielny Publiczny Secjalistyczny Szpital Zachodni im. sw. Jana Pawla II, Grodzisk Mazowiecki, Poland
🇵🇱
Specjalistyczne Centrum Medyczne Panacea Poznan, Krakow, Poland

Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants

Phase 1

Completed

Conditions: Heart Decompensation, Acute

Interventions: Drug: BMS-986231

First Posted Date: 2017-07-07

Last Posted Date: 2017-08-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT03210909

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: HNO Donor
Drug: Placebo

First Posted Date: 2017-01-10

Last Posted Date: 2021-01-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 329

Registration Number: NCT03016325

Locations: 🇺🇸
DMC Detroit Receiving Hospital, Detroit, Michigan, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

and more 22 locations

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

Phase 1

Completed

Conditions: Heart Decompensation, Acute

Interventions: Drug: BMS-986231
Drug: BMS-986231 Placebo

First Posted Date: 2016-10-13

Last Posted Date: 2017-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 56

Registration Number: NCT02932969

Locations: 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

Phase 2

Completed

Conditions: Heart Failure
Decompensated Heart Failure
Acute Heart Failure

Interventions: Drug: Placebo
Drug: CXL-1427

First Posted Date: 2014-06-06

Last Posted Date: 2019-07-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT02157506

Locations: 🇷🇺
Cardioxyl Study Site, Tomsk, Russian Federation
🇵🇱
Cardioxyl Study SIte, Warsaw, Poland

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy